PARNAXLAB · NSE
Parnax Lab Limited
₹118.22
-4.55% (-₹5.64)
Prev. close
₹123.86
Volume
11,075
Delivery %
74.6%
As of
25 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Parnax Lab Limited
Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products. It also provides oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services. The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. Parnax Lab Limited was incorporated in 1982 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mihir Prakash Shah
Headquarters
Mumbai
Employees
12
Website
naxparlab.comExchange
View on NSE ↗Key stats
P/E ratio (TTM)
15.5
EPS (TTM)
₹7.79
Beta (5Y monthly)
0.03
Shares float
28.47 L
EPS · quarter ended Jun 2026
₹0.37
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹89.52 Cr | ₹163.03 Cr | ₹167.61 Cr | ₹188.71 Cr | ₹187.74 Cr | ₹248.54 Cr | |
| EBITDA | — | — | ₹23.71 Cr | ₹24.28 Cr | ₹28.29 Cr | ₹29.50 Cr |
| ₹-36.20 L | ₹8.26 Cr | ₹8.62 Cr | ₹9.61 Cr | ₹11.52 Cr | ₹11.78 Cr | |
| Diluted EPS | — | — | ₹7.79 | ₹8.37 | ₹10.05 | ₹10.27 |
Depreciation & amortisation, EBITDA, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹106.26 Cr | ₹153.46 Cr | ₹145.07 Cr | ₹190.26 Cr | ₹189.82 Cr | ₹227.63 Cr | |
| ₹58.90 Cr | ₹69.07 Cr | ₹54.72 Cr | ₹80.64 Cr | ₹69.53 Cr | ₹82.78 Cr | |
| Stockholders' equity | ₹32.54 Cr | ₹48.19 Cr | ₹62.15 Cr | ₹71.57 Cr | ₹83.10 Cr | ₹95.14 Cr |
Trade receivables, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹20.91 Cr | ₹15.88 Cr | ₹32.30 Cr | ₹8.00 Cr | |
| Investing cash flow | — | — | ₹-9.92 Cr | ₹-31.52 Cr | ₹-16.39 Cr | ₹-16.39 Cr |
| — | — | ₹-14.07 Cr | ₹14.82 Cr | ₹-15.82 Cr | ₹8.18 Cr | |
| Capital expenditure | — | — | ₹-11.28 Cr | ₹-32.49 Cr | ₹-18.58 Cr | ₹-35.46 Cr |
| End cash position | — | — | ₹1.28 Cr | ₹45.78 L | ₹54.99 L | ₹33.64 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| Parnax Lab Limited | — | ₹123.86 | 16.5 | — | 12.4% | 0.87 | +32.4% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.